November 2025 – Page 2 – Clinical Trial Results

Dr. Christopher Wong and Dr. C. Michael Gibson Discuss: DECAF – The Does Eliminating Coffee Avoid Fibrillation (DECAF) Trial

November 9, 2025

Disclosures: TBD

Dr. Amrish Deshmukh and Dr. C. Michael Gibson Discuss: META-AF – Metformin as an Adjunctive Therapy to Catheter Ablation of Atrial Fibrillation

November 9, 2025

Disclosures: TBD

Dr. Kevin Alexander and Dr. C Michael Gibson discuss: Acoramidis Effect on All-Cause Mortality in Patients with p.V142I (V122I) Variant ATTR-CM: Findings From the ATTRibute-CM Study

November 8, 2025

Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.

Dr. Atul Verma and Dr. C. Michael Gibson Discuss: OCEAN – The Need for Ongoing Oral Anticoagulation in Patients with Clinical Stroke Risk Factors After Successful Catheter Ablation of Atrial Fibrillation: The OCEAN Randomized Trial

November 8, 2025

Disclosures: TBD

Dr. Ulf Landmesser and Dr. C. Michael Gibson Discuss: CLOSURE-AF – Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy

November 8, 2025

Disclosures: TBD

Dr. Yohei Sotomi and Dr. C. Michael Gibson Discuss: OPTIMA-AF Trial – Short Dual Antithrombotic Therapy after PCI in Patients with Atrial Fibrillation: OPTIMA-AF trial

November 8, 2025

Disclosures: TBD

Dr. Jung-Sun Kim and Dr. C. Michael Gibson Discuss: ADAPT AF-DES – Appropriate Duration of Antiplatelet and Thrombotic Strategy after 12 Months in Patients with Atrial Fibrillation Treated with Drug-Eluting Stents

November 8, 2025

Disclosures: TBD

Dr. Mary McDermott and Dr. C. Michael Gibson discuss the PERMET trial: Can metformin improve walking performance in nondiabetic patients with peripheral artery disease?

November 8, 2025

https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.21358?guestAccessKey=529478e8-ab34-447b-b88f-7fbe78cf4342 © 2025 American Medical Association. All rights reserved, including those for text and data mining, AI training, and similar […]

Dr. Jeffrey I Weitz and Dr. C. Michael Gibson Discuss: ROXI~ Two Mechanistically Distinct Factor XI Antibodies, REGN9933 and REGN7508, for the Prevention of Venous Thromboembolism After Knee Arthroplasty: the ROXI-VTE-I and ROXI-VTE-II trials

November 8, 2025

Disclosures: TBD

Dr. Paul Burton and Dr. C. Michael Gibson Discuss: Effect of Evolocumab in Patients at High Cardiovascular Risk without Prior Myocardial Infarction or Stroke: Primary Results of the VESALIUS-CV trial

November 8, 2025

Disclosures: TBD